Skip to main content

Table 4 Summary table of RFS rates observed in the prospective registry cohort and retrospective archival studies

From: Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test

Study

n

Non-event follow-up time

Event time

Class 1 1.5-year RFS

Class 2 1.5-year RFS

Median, years

Median, years

Percent (95% CI*)

Percent (95% CI)

Initial validation (Gerami, 2015)

104

8.2

1.7

98% (95–100%)

70% (58–85%)

Independent validation

523

7.2

1.2

95% (92–97%)

67% (61–74%)

All retrospective studies to date

782

6.9

1.3

95% (93–97%)

67% (62–73%)

Current study

322

1.5

1.0

97% (95–100%)

77% (67–87%)

  1. *CI confidence interval